Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
PR Newswire•20/10/2026•08:09 ET
0
Key Highlights
- ➤$50 million private placement priced at approximately $7.93 per share
- ➤Financing covers approximately 5.17 million shares and 1.13 million pre-funded warrant shares
- ➤Atrium shares fell approximately 44% from pre-HARBOR levels near $14
- ➤Bristol Myers Squibb collaboration offers up to $2.175 billion in milestones
- ➤Yakira urges strategic review, spending controls and financing explanation
Expert Statements
Bruce Kallins, President of Yakira Capital Management
“The Board's responsibility is to maximize long-term shareholder value, not simply finance the continuation of the standalone strategy.”
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing PR Newswire
Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a valuation near fifty percent of net cash
Get started
Create a free account to read the full story.